Janux is a biotech company developing next-generation therapeutics. Keeping up with SEC guidance with a relatively small team while consistently delivering quarterly reports was becoming a challenge. New ActiveDisclosure enabled Janux to deliver on-time and accurate SEC filing with unparalleled expertise and service.
How We Helped a Newly Public Biotechnology Company Save Time, Drive Efficiencies, and Optimize SEC Filing
To learn more, download the case study below.